Selective removal of alloreactive cells from haematopoietic stem cell grafts: Graft engineering for GVHD prophylaxis

Bone Marrow Transplantation

Volumn 23, Issue 10, 1999, Pages 1071-1079

  Koh, M B C ^a   Prentice, H G ^a,b   Lowdell, M W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Allogeneic BMT; Alloreactivity; CD69; Graft versus leukaemia; GVHD; T cell depletion

Indexed keywords

ANTILEUKEMIC AGENT; CD69 ANTIGEN; GAMMA INTERFERON; HLA ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOIMMUNITY; ANTIGEN BINDING; ANTIVIRAL ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL SELECTION; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CRYOPRESERVATION; DONOR; FEASIBILITY STUDY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOPHENOTYPING; IRRADIATION; LYMPHOCYTE TRANSFER; MIXED LYMPHOCYTE CULTURE; MONONUCLEAR CELL; PRIORITY JOURNAL; RELAPSE; T LYMPHOCYTE;

EID: 0032968981     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701749     Document Type: Article

References (35)

1. Korngold R, Sprent J. T cell subsets and GVHD. Transplantation 1987; 44: 335-339.
2. Dicke KA, Hooft JI van, Bekkum DW van. The selective elimination of immunologically competent cells from bone marrow and lymphatic cell mixtures. II. Mouse spleen cell fractionation on a discontinuous albumin gradient. Transplantation 1968; 6: 562-570.
3. Prentice HG, Janossy G, Blacklock HA et al. Use of anti-cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone marrow transplantation for acute leukaemia. Lancet 1982; 1: 700-703.
4. Apperly JF, Jones L, Hale G et al. Bone marrow transplantation for patients with chronic myeloid leukaemia: T cell depletion with Campath-1 reduces the incidence of acute GVHD but may increase the risk of leukaemia relapse. Bone Marrow Transplant 1986; 1: 53-66.
5. Martin PJ, Hansen JA, Buckner CD et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 1985; 66: 664-672.
6. Hale G, Waldman H. Depletion of T cells with Campath I and human complement. Analysis of GVHD and graft failure in a multi-centre study. Bone Marrow Transplant 1986; 1 (Suppl.1): 93-94.
7. Marmont AM, Horowitz MM, Gale RP et al. T cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120-2130.
8. Lowdell MW, Craston R, Ray N et al. The effect of T cell depletion with Campath-1M on immune reconstitution after chemotherapy and allogeneic bone marrow transplant as treatment for leukaemia. Bone Marrow Transplant 1998; 21: 679-686.
9. Patterson J, Prentice HG, Brenner MK et al. Graft rejection following HLA-matched T-lymphocyte-depleted bone marrow transplantation. Br J Haematol 1986; 63: 221-230.
10. + T cells to GVHD and GVL reactivity after transplantation of MHC compatible marrow. Bone Marrow Transplant 1991; 8: 51-58.
11. + T lymphocytes for allogeneic bone marrow transplantation: engraftment, GVHD and GVL. Prog Clin Biol Res 1992; 377: 395-398.
12. Glass B, Uharek L, Gassmann W et al. GVL activity after BMT does not require GVHD. Ann Haematol 1992; 64: 255-259.
13. Jiang ZY, Barren AJ, Goldman JM, Mavroudis DA. Association of natural killer cell immune recovery with a GVL effect independent of GVHD after allogeneic bone marrow transplantation. Ann Haematol 1997; 74: 1-6.
14. Jiang YZ, Barren AJ. Cellular and cytokine mediated effects of CD4-positive lymphocyte lines generated in vitro against CML. Exp Hematol 1995; 23: 1167-1172.
15. Prentice HG, Sekhar M, Popat U et al. Donor leucocyte infusions for relapsed acute leumaemias post-BMT. Blood 1995; 86 (Suppl.): 566a.
16. Kolb HJ, Schattenberg A, Goldman JM et al. GVL effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukaemia. Blood 1995; 86: 2041-2050.
17. Giralt S, Hester J, Huh Y et al. CD8 depleted donor lymphocyte infusion as treatment for relapsed CML after allogeneic BMT: GVL without GVHD. Blood 1995; 86: 4337-4343.
18. Van Rhee F, Lin F, Cullis JO et al. Relapse of CML after allogeneic BMT: the case for giving DLI before the onset of haematological relapse. Blood 1994; 83: 3377-3383.
19. Mavroudis DA, Jiang YZ, Hensel N et al. Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to GVHD prophylaxis in haploidentical bone marrow transplantation. Bone Marrow Transplant 1996; 17: 793-799.
20. Cavazzana-Calvo M, Stephan JL, Sarnacki S et al. Attenuation of GVHD and graft rejection by ex vivo immunotoxin elimination of alloreactive T cells in an H-2 haplotype disparate mouse combination. Blood 1994; 83: 288-298.
21. Datta AR, Barrett AJ, Jiang YZ et al. Distinct T cell populations distinguish CML cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions. Bone Marrow Transplant 1994; 14: 517-524.
22. Cavazzana-Calvo M, Fromont C, Le Deist F et al. Specific elimination of alloreactive T cells by an anti-IL2 receptor B chain specific immunotoxin. Transplantation 1990; 50: 1-7.
23. Rencher SD, Houston JA, Lockey TD, Hurwitz JL. Eliminating GVH potential from T cell immunotherapeutic populations. Bone Marrow Transplant 1996; 18: 415-420.
24. Testi R, D'Ambrosio D, De Maria R, Santoni A. The CD69 receptor: a multipurpose cell surface trigger for haematopoietic cells. Immunol Today 1994; 15: 479-483.
25. Cebrian M, Yague E, Rincon M et al. Triggering of T cell proliferation through AIM, an activation inducer molecule expressed on activated human lymphocytes. J Exp Med 1988; 168: 1621-1637.
26. Craston R, Koh M, McDermott A et al. Temporal dynamics of CD69 expression on lymphoid cells. J Immunol Meth 1997; 209: 37-45.
27. Bishara A, Bautbar C, Nagler A et al. Prediction by a modified mixed leucocyte reaction assay of GVHD and graft rejection after allogeneic bone marrow transplantation. Transplantation 1994; 57: 1474-1479.
28. 3H thymidine incorporation and CD69 expression in the evaluation of T cell function following allogeneic bone marrow transplantation. Hum Immunol 1997; 55 (Suppl.): 73 (Abstr. 70).
29. Simms PE, Ellis TM. Utility of flow cytometric detection of CD69 expression as a rapid method for determining poly and oligoclonal lymphocyte activation. Clin Diag Lab Immunol 1996; 3: 301-304.
30. Goulmy E. Minor histocompatibility antigens in man and their role in transplantation. In: Morris PJ, Tilney NL (eds). Transplant Reviews, Vol. 2. WB Saunders: Philadelphia, 1988, pp 29-54.
31. Thornhill MH, Wellicome SM, Mahiouz DL et al. Tumour necrosis factor combines with IL-4 or IFN-g to selectively enhance endothelial cell adhesiveness for T cells. J Immunol 1991; 146: 592-598.
32. Collins T, Lapierre LA, Fiers W et al. Recombinant human tumour necrosis factor increases mRNA levels and surface expression of HLA-AB in vascular endothelial cells and dermal fibroblasts in vitro. Proc Natl Acad Sci USA 1986; 83: 446-450.
33. Sclomchik WD, Emerson SG. Immunobiology of T cell therapies for Leukaemias. Acta Haematol 1996; 96: 189-213.
34. Antin JH, Ferrara JLM. Cytokine dysregulation and acute GVHD. Blood 1992; 80: 2964-2968.
35. Vogelsang GB, Hess AD. GVHD - new directions for a persistent problem. Blood 1984; 84: 2061-2067.